IDEAYA Biosciences Inc at JPMorgan Healthcare Conference Transcript
Let's get started. This is the Tuesday afternoon of the 41st Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by my colleagues, Priyanka Grover and Malcolm Kuno from the team. Our next presenting company is IDEAYA, and presenting on behalf of the company, we have CEO Yujiro Hata.
Good afternoon. Thank you, Anupam, for that nice introduction. And thank you to JPMorgan for the opportunity to present at the 41st Annual JPMorgan Healthcare Conference. We'll be making some forward-looking statements today. Please refer to our SEC filings as appropriate.
At the start of 2023, on Monday, we made a key announcement on the IND clearance and the Phase 1 start for our third potential first-in-class precision medicine oncology program in IDE161. We believe this is a key milestone for us and continues our strategy to build a diversified pipeline in the area of synthetic lethality.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
